Basic Information
| RNALocate ID: | RLID:11004049 |
| RNA Symbol: | hsa-miR-629-5p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-629 |
| RNA ID: | miRBase:MIMAT0004810 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23539611 |
| Tissue/Cell Line: | Seminal plasma |
| Method: | Microarray |
| Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002687 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01002688 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01002689 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11004045 | Exosome | Plasma | 23663360 |
| RLID:11004046 | Exosome | K562 cells | 24460325 |
| RLID:11004047 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
| RLID:11004048 | Microvesicle | Plasma | 23077538 |
| RLID:11004050 | Microvesicle | Follicular fluid | 23666971 |
| RLID-D:11000704 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine | |
| RLID-D:11001579 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-629-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-64183 |
| MNDR | hsa-miR-629-5p | Large cell neuroendocrine cancer | MNDR-E-MI-64184 |
| MNDR | hsa-miR-629-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-64185 |
| MNDR | hsa-miR-629-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-64186 |
| MNDR | hsa-miR-629-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-64187 |
| MNDR | hsa-miR-629-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-64188 |
| MNDR | hsa-miR-629-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-64189 |
| MNDR | hsa-miR-629-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-64190 |
| MNDR | hsa-miR-629-5p | Her2-receptor positive breast cancer | MNDR-E-MI-64191 |
| MNDR | hsa-miR-629-5p | Breast cancer luminal | MNDR-E-MI-64192 |
| MNDR | hsa-miR-629-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-64193 |
| MNDR | hsa-miR-629-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-64194 |
| MNDR | hsa-miR-629-5p | Small intestine cancer | MNDR-E-MI-64195 |
| MNDR | hsa-miR-629-5p | Prostate cancer | MNDR-E-MI-64196 |
| MNDR | hsa-miR-629-5p | Alzheimer disease | MNDR-E-MI-64197 |
| MNDR | hsa-miR-629-5p | Esophageal carcinoma | MNDR-E-MI-64198 |
| MNDR | hsa-miR-629-5p | Dysautonomia familial | MNDR-E-MI-64199 |
| MNDR | hsa-miR-629-5p | Leukemia | MNDR-E-MI-64200 |
| MNDR | hsa-miR-629-5p | Cardiovascular disease | MNDR-E-MI-64201 |
| MNDR | hsa-miR-629-5p | Lung cancer | MNDR-E-MI-64202 |
| MNDR | hsa-miR-629-5p | Down syndrome | MNDR-E-MI-64203 |
| MNDR | hsa-miR-629-5p | Parkinson disease | MNDR-E-MI-64204 |
| MNDR | hsa-miR-629-5p | Breast cancer | MNDR-E-MI-64205 |
| MNDR | hsa-miR-629-5p | Thyroid cancer | MNDR-E-MI-64206 |
| MNDR | hsa-miR-629-5p | Pituitary neoplasms | MNDR-E-MI-64207 |
| MNDR | hsa-miR-629-5p | Pancreatic cancer | MNDR-E-MI-64208 |
| MNDR | hsa-miR-629-5p | Melanoma | MNDR-E-MI-64209 |
| MNDR | hsa-miR-629-5p | Colon cancer | MNDR-E-MI-64210 |
| MNDR | hsa-miR-629-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-64211 |
| MNDR | hsa-miR-629-5p | Familial ovarian cancer | MNDR-E-MI-64212 |
| MNDR | hsa-miR-629-5p | Acromegaly | MNDR-E-MI-64213 |
| MNDR | hsa-miR-629-5p | Prostate adenocarcinoma | MNDR-E-MI-64214 |
| MNDR | hsa-miR-629-5p | Carcinoma ductal breast | MNDR-E-MI-64215 |
| MNDR | hsa-miR-629-5p | Glioblastoma | MNDR-E-MI-64216 |
| MNDR | hsa-miR-629-5p | Glioma | MNDR-E-MI-64217 |
| MNDR | hsa-miR-629-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-64218 |
| MNDR | hsa-miR-629-5p | Osteosarcoma | MNDR-E-MI-64219 |
| MNDR | hsa-miR-629-5p | Cervical squamous cell carcinoma | MNDR-E-MI-64220 |
| MNDR | hsa-miR-629-5p | Pituitary adenoma | MNDR-E-MI-64221 |
| MNDR | hsa-miR-629-5p | Lung squamous cell carcinoma | MNDR-E-MI-64222 |
| MNDR | hsa-miR-629-5p | Lung adenocarcinoma | MNDR-E-MI-64223 |
| MNDR | hsa-miR-629-5p | Thyroid carcinoma | MNDR-E-MI-64224 |
| MNDR | hsa-miR-629-5p | Bladder urothelial carcinoma | MNDR-E-MI-64225 |
| MNDR | hsa-miR-629-5p | Pancreatic adenocarcinoma | MNDR-E-MI-64226 |
| MNDR | hsa-miR-629-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-64227 |
| MNDR | hsa-miR-629-5p | Carcinoma renal cell | MNDR-E-MI-64228 |
| MNDR | hsa-miR-629-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-64229 |
| MNDR | hsa-miR-629-5p | Clear cell renal cell carcinoma | MNDR-E-MI-64230 |
| MNDR | hsa-miR-629-5p | Biliary tract cancer | MNDR-E-MI-64231 |
| MNDR | hsa-miR-629-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-64232 |
| MNDR | hsa-miR-629-5p | Leukoencephalopathy progressive multifocal | MNDR-E-MI-64233 |
| MNDR | hsa-miR-629-5p | Breast invasive carcinoma | MNDR-E-MI-64234 |
| MNDR | hsa-miR-629-5p | Hepatocellular carcinoma | MNDR-E-MI-64235 |
| MNDR | hsa-miR-629-5p | Familiar ovarian carcinoma | MNDR-E-MI-64236 |
| MNDR | hsa-miR-629-5p | Barrett's adenocarcinoma | MNDR-E-MI-64237 |
| MNDR | hsa-miR-629-5p | Hodgkin lymphoma | MNDR-E-MI-64238 |
| MNDR | hsa-miR-629-5p | Ulcerative colitis | MNDR-E-MI-64239 |
| MNDR | hsa-miR-629-5p | Crohn disease | MNDR-E-MI-64240 |
| MNDR | hsa-miR-629-5p | Skin cutaneous melanoma | MNDR-E-MI-64241 |
| MNDR | hsa-miR-629-5p | Skin melanoma | MNDR-E-MI-64242 |
| MNDR | hsa-miR-629-5p | Acute myelocytic leukemia | MNDR-E-MI-64243 |
| MNDR | hsa-miR-629-5p | Colorectal cancer | MNDR-E-MI-64244 |
| MNDR | hsa-miR-629-5p | Nasopharynx carcinoma | MNDR-E-MI-64245 |
| MNDR | hsa-miR-629-5p | Nasopharyngeal cancer | MNDR-E-MI-64246 |
| MNDR | hsa-miR-629-5p | Epstein-barr virus infections | MNDR-E-MI-64247 |
| MNDR | hsa-miR-629-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-64248 |
| MNDR | hsa-miR-629-5p | Chronic pain | MNDR-E-MI-64249 |
| MNDR | hsa-miR-629-5p | Stroke lacunar | MNDR-E-MI-64250 |
| MNDR | hsa-miR-629-5p | Barrett's carcinogenesis | MNDR-E-MI-64251 |
| MNDR | hsa-miR-629-5p | Breast cancer her3+ negative | MNDR-E-MI-64252 |
| MNDR | hsa-miR-629-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-64253 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | HNF4A | Homo sapiens | RR00715562 |
TOP